• MORE MARKET STATS

Pallavi Ail

Articles By Pallavi Ail

68 Articles

Drug firms face ANDA blues

The delay in approval of generic drug applications, which has been slowly declining annually, witnessed its lowest run-rate in the first half of...

Power pact: JSW Energy all charged up with JPVL buy

JPVL buy helps JSW Energy re-balance power assets portfolio in favour of fixed PPAs

Power pact: JSW Energy all charged up with JPVL buy

Deal clincher: Sun hoists its flag on domestic pharma landscape

Competition Commission has asked Sun Pharma to divest one drug and Ranbaxy six over the next six months to ensure competition in the market

Deal clincher: Sun hoists its flag on domestic pharma landscape

Drug cos slam proposed ban on using plastic containers

The Indian Drug Manufacturers’ Association (IDMA) has written to the ministry of health and family...

Drug cos slam proposed ban on using plastic containers

Diagnostic firms bet big on ‘prevention better than cure’

Players in fragmented industry hope to grow by offering specialised tests, especially those for predicting diseases

There is no workforce better than India’s: Rajiv Malik, Mylan

Mylan is the world’s second-largest generic drug player in terms of revenue.

There is no workforce better than India’s: Rajiv Malik, Mylan

Indians now among biggest tipsters to US SEC

If statistics emerging from the US are any indication, Indians have a penchant for whistleblowing.

Gautam Adani’s Power Play: Short of cash flows but not on ambition

Although Adani Power is highly leveraged, it continues to shop for assets

There is more reason to invest in wind than in solar: Rahul Shah, CEO, TPREL

Tata Power Renewable Energy Limited (TPREL), a subsidiary of Tata Power, is looking to add nearly 200MW of capacity annually by spending close to R1,400 crore...

There is more reason to invest in wind than in solar: Rahul Shah, CEO, TPREL

Consolidation in US hurts Indian generic firms Dr Reddy’s Lab, Sun Pharma

Consolidation of pharma supply chains in the US is starting to hurt revenues of Indian generics players, whose sales come mainly from US market.

Lupin biocom

USFDA restrictions hurt Wockhardt’s fortunes

Analysts say drug maker will need another year to resolve issues

USFDA restrictions hurt Wockhardt’s fortunes

JSW Energy puts on hold decision to buy Jaypee’s 500-MW Bina plant

JSW Energy has put on hold its decision to buy a 500-MW thermal power plant in Bina, Rajasthan, from the Jaypee Group...

JSW Energy puts on hold decision to buy Jaypee’s 500-MW Bina plant

BEST seeks property tax hike; eyes R500 crore to feed deficit

BEST has written to the city municipal authority, asking them to increase the property tax in such a manner that...

BEST seeks property tax hike; eyes R500 crore to feed deficit

Sun Pharma didn’t have corrective plan to address issues behind recalls: USFDA

Of the 23 observations raised by the US Food and Drug Administration during...

Sun Pharma didn’t have corrective plan to address issues behind recalls: USFDA
Advertisement
Income Tax Calculator, Budget 2019, How to Calculate Income Tax

 

Stock Market

Advertisement
Advertisement